ELOX Eloxx Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1035354 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-38.6%
ROA-27.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets29.5%
Debt / equity0.00x
Current ratio3.39x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.17x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $6.36M | $0 | — | — |
| R&D expense | $3.06M | $3.58M | $8.60M | $23.73M | $22.90M |
| SG&A expense | $3.38M | $5.25M | $8.69M | $10.69M | $20.45M |
| Operating income | -$6.44M | -$2.47M | -$17.29M | -$34.42M | -$66.02M |
| Pretax income | -$6.00M | -$3.14M | -$17.05M | -$36.06M | -$66.73M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.00M | -$3.14M | -$17.05M | -$36.06M | -$66.73M |
| EBITDA | -$6.44M | -$2.43M | -$17.18M | -$34.34M | -$65.90M |
| EPS (basic) | -0.49 | -0.84 | -6.63 | -16.65 | -38.15 |
| EPS (diluted) | -0.49 | -0.84 | -6.63 | -16.65 | -38.15 |
| Weighted avg. shares (diluted) | 12.35M | 3.76M | 2.57M | 2.17M | 1.75M |
| Balance sheet | |||||
| Cash & equivalents | $4.79M | $111,000 | $1.13M | $19.21M | $42.27M |
| Current assets | $5.27M | $2.98M | $1.55M | $20.13M | $43.48M |
| PP&E, net | $0 | $0 | $35,000 | $169,000 | $216,000 |
| Total assets | $5.27M | $2.98M | $1.71M | $21.12M | $45.14M |
| Current liabilities | $17.18M | $27.31M | $22.70M | $23.09M | $9.96M |
| Short-term debt | $1.00M | $6.52M | $2.22M | $3.98M | $0 |
| Long-term debt | $0 | $0 | $1.61M | $8.56M | $12.00M |
| Total debt | $1.00M | $6.52M | $3.83M | $12.54M | $12.00M |
| Total liabilities | $17.18M | $27.31M | $24.31M | $31.78M | $22.75M |
| Shareholders' equity | -$11.91M | -$24.34M | -$22.60M | -$10.66M | $22.38M |
| Net debt | -$3.79M | $6.41M | $2.70M | -$6.67M | -$30.27M |
| Shares outstanding | 435,432 | 3.53M | 3.14M | 2.17M | 2.17M |
| Cash flow statement | |||||
| Operating cash flow | -$6.33M | -$4.71M | -$14.34M | -$31.84M | -$35.00M |
| Capital expenditure | — | — | — | $66,000 | $89,000 |
| Free cash flow | — | — | — | -$31.91M | -$35.09M |
| Investing cash flow | $1,000 | $38,000 | $309,000 | -$66,000 | $2.06M |
| Financing cash flow | $11.00M | $3.44M | -$4.08M | $8.81M | $50.79M |
| Depreciation & amortization | $0 | $35,000 | $113,000 | $77,000 | $114,000 |
| Stock-based compensation | $235,000 | $541,000 | $1.97M | $3.02M | $9.17M |
Free plan shows the latest 5 periods; Pro shows all 30 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.